Biocon, Mylan deal

Mylan partnered with Biocon to develop and commercialize Biocon's biosimilar versions of three insulin analog products - glargine, aspart and lispro. Mylan said the companies will share development costs. Mylan will have exclusive commercialization rights in the U.S., Canada, Australia, New Zealand, the EU and the European Free Trade Association countries, and will have exclusive co-commercialization rights with Biocon in undisclosed markets. Biocon's biosimilar glargine is in Phase I testing for Type I diabetes, while the company's biosimilar aspart and lispro are in preclinical testing. The companies declined to disclose financial details.

Last March, Biocon and Pfizer Inc. (NYSE:PFE, New York, N.Y.) terminated a 2010 deal to market Biocon's biosimilar versions of insulin and insulin analog products, including glargine, aspart and lispro (see BioCentury, March 19, 2012). ...